Latest news
Loading news…
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes.
ViaCyte was acquired by Vertex Pharmaceuticals in 2022 for $320M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
89
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- San Diego, California, United States
Key People at ViaCyte
Vice President Intellectual Property Counsel Diversity & Inclusion Officer
Vice President, Regulatory and Quality
Vice President, Human Resources
Senior Vice President of Business Development and Operations
President and CEO
CTO
Vice President, Head of Clinical Development
89
professional contacts at ViaCyte
Contact execs at ViaCyte →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to ViaCyte
Loading news…
FAQs about ViaCyte
People who checked this page also checked these
Browse the full Acquirezy directory.